Linzess (linaclotide) is a prescription drug that’s used to treat certain kinds of constipation. The drug comes as an oral capsule. Linzess may be safe to take while pregnant or breastfeeding. Keep ...

Linzess comes as a capsule that you swallow. Keep reading for details on Linzess and cost and how to save money on prescriptions. Note: For more details on Linzess, see this in-depth article. The ...

Ironwood Pharmaceuticals, Inc. IRWD along with partner Allergan AGN announced positive top-line data from the phase IIIb study on Linzess (linaclotide) for treating multiple abdominal symptoms in ...

Irritable bowel syndrome with constipation (IBS-C) is characterized by symptoms such as irregular bowel movements, abdominal pain, and bloating. The U.S. Food and Drug Administration (FDA) has ...

Linzess can cause certain side effects, some of which are more common than others. These side effects may be temporary, lasting a few days to weeks. However, if the side effects last longer than that, ...

A long time ago in a galaxy far, far away, an IBS drug called Zelnorm was launched. Unique in the universe, Zelnorm’s DTC campaign famously used words and images drawn on naked tummies. Although that ...

Inform your doctor of all medications, supplements, and health conditions that apply to you before taking Linzess to prevent possible interactions. Linzess may interact with antidiarrheal and ...

On Aug 13, we issued an updated research report on Ironwood Pharmaceuticals, Inc. IRWD. This biopharmaceutical company, based in Cambridge, MA, is focused on the development and commercialization of ...

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) approved a revised label for ...

Linzess is a prescription medication used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). It works by increasing fluid in the intestines and ...

– Reiterates 2025 guidance of LINZESS U.S. net sales of $800-$850 million and total Ironwood revenue of $260-290 million – – LINZESS (Iinaclotide) EUTRx prescription demand growth in Q1 2025 of 8% ...